Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

EMARegulator guidanceBioequivalenceMedicinesHigh confidenceLast verified October 4, 2026

CPMP/EWP/QWP/1401/98 Rev 1

Guideline on the investigation of bioequivalence

Current edition

Revision 1 (since 1 August 2010); parts replaced by ICH M13A in 2025

About this standard

Sets requirements for the design, conduct and evaluation of bioequivalence studies for immediate-release forms with systemic action, including the conditions for waiving studies.

Since 25 January 2025 ICH M13A replaces the parts of this guideline on non-replicate study designs. Other topics, such as replicate designs for highly variable drugs and narrow therapeutic index drugs, still apply.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

  • AustraliaAdopted with changes
    Edition accepted
    -
    National code
    CPMP/EWP/QWP/1401/98 Rev. 1/Corr

    Adopted guidelines are generally not required by law but give sponsors guidance on meeting the legal requirements.. Adopted with annotations: Good Clinical Practice follows the TGA-annotated EU note, and a generic application generally includes a bioequivalence study against an Australian leading brand.

  • SwitzerlandReferenced
    Edition accepted
    -
    National code
    -

    Partial recognition. Appendix II for rapid release non-oral forms; ICH M13A applies to rapid release oral forms.

  • Saudi ArabiaReferenced
    Edition accepted
    -
    National code
    -

    The SFDA Guidelines for Bioequivalence are adapted from this EMA guideline, with Saudi additions such as the reference product rule and the subject numbers.

  • SingaporeReferenced
    Edition accepted
    -
    National code
    -

    HSA advises applicants to know the ASEAN bioequivalence guideline, which was adopted from this EMA guideline, and to refer to EMA CHMP or US FDA guidelines for the conduct and analysis of bioequivalence studies.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube